Exacerbation of choroidal and retinal pigment epithelial atrophy after anti-vascular endothelial growth factor treatment in neovascular age-related macular degeneration
The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
PURPOSE: To study the progression of retinal pigment epithelium (RPE) and choroidal atrophy in patients with neovascular age-related macular degeneration (AMD) and to assess for a possible association with the number and type of anti-vascular endothelial growth factor treatments. METHODS: Patients with neovascular AMD and a minimum of 1-year follow-up were reviewed. Fellow eyes with nonneovascular AMD were used as control eyes. Retinal pigment epithelial atrophy area and choroidal thickness were determined using spectral-domain optical coherence tomography. Multivariable regression models were used for statistical analyses. RESULTS: A total of 415 eyes were included in the study, with a mean follow-up of 2.2 years. Eyes with neovascular AMD had greater progression of RPE atrophy and choroidal atrophy compared with those with nonneovascular AMD (P < 0.001). Progression of RPE atrophy and choroidal atrophy was independently associated with the total number of injections of bevacizumab and ranibizumab (all P values ≤ 0.001). In the subgroup of 84 eyes with neovascular AMD and without RPE atrophy at baseline, only bevacizumab was associated with the progression of RPE atrophy (P = 0.003). This study likely lacked statistical power to detect an association with ranibizumab in this subgroup. CONCLUSION: Retinal pigment epithelial atrophy and choroidal atrophy in neovascular AMD seem to be exacerbated by anti-vascular endothelial growth factor treatment. Possible differences between bevacizumab and ranibizumab require further investigation.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Unfortunately, up to 30% of patients can still have intraretinal fluid with vision loss after 1 year of therapy [2–4].”
From Thrombospondin-1, BIM and CFH polymorphisms and response to anti-VEGF treatment in neovascular age- related macular degeneration patients (2024) · cites this paper as [3]
Citations
Cites
Ranibizumab and Bevacizumab for Treatment of Neovascular Age-related Macular Degeneration
Martin, D. F., Maguire, M. G., Fine, S. L., Ying, G.-S., Jaffe, G. J., Grunwald, J. E., Toth, C., Redford, M., & Ferris, F. L. (2012) · Ophthalmology · doi:10.1016/j.ophtha.2012.03.053 · Cited by 1,715 · cited 5×
“9 years, which is comparable to the 2-year follow-up of the CATT.(2) The CATT results showed that depending on treatment protocol, 12.”
MethodResultInfluentialSeven-Year Outcomes in Ranibizumab-Treated Patients in ANCHOR, MARINA, and HORIZON
Rofagha, S., Bhisitkul, R. B., Boyer, D. S., Sadda, S. R., & Zhang, K. (2013) · Ophthalmology · doi:10.1016/j.ophtha.2013.03.046 · Cited by 1,023 · cited 1×
“A recent study looking at ranibizumab trials with 7 years of follow-up showed that the strongest correlation for poor visual outcome was the increased area of macular atrophy.(19) Based on the results of our study, it would seem reasonable to conclude that this macular atrophy progression may have at least in part bee…”
ResultDelori, F. C., Dorey, C. K., Staurenghi, G., Arend, O., Goger, D. G., & Weiter, J. J. (1995) · PubMed · Cited by 948
Incidence and Progression of Geographic Atrophy
Joachim, N., Mitchell, P., Kifley, A., Rochtchina, E., Hong, T., & Wang, J. J. (2013) · Ophthalmology · doi:10.1016/j.ophtha.2013.03.029 · Cited by 96
Cited by
Risk of geographic atrophy in the comparison of age-related macular degeneration treatments trials
Grunwald, J. E., Daniel, E., Huang, J., Ying, G.-S., Maguire, M. G., Toth, C. A., Jaffe, G. J., Fine, S. L., Blodi, B., Klein, M. L., et al. (2014) · Ophthalmology · doi:10.1016/j.ophtha.2013.08.015 · Cited by 590
A paradigm shift in imaging biomarkers in neovascular age-related macular degeneration
Schmidt-Erfurth, U., & Waldstein, S. M. (2016) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2015.07.007 · Cited by 390
“Several studies identified an association between the number of antiangiogenic treatments over time and the growth rate of RPE atrophy (Grunwald et al., 2014a, 2014b; Young et al., 2014).”
BackgroundStem cell based therapies for age-related macular degeneration: The promises and the challenges
Nazari, H., Zhang, L., Zhu, D., Chader, G. J., Falabella, P., Stefanini, F., Rowland, T., Clegg, D. O., Kashani, A. H., Hinton, D. R., et al. (2015) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2015.06.004 · Cited by 206
“There is also evidence that the underlying atrophic component of AMD still progresses despite using anti-VEGF therapy (Young et al., 2014).”
BackgroundGrowth of Geographic Atrophy in the Comparison of Age-related Macular Degeneration Treatments Trials
Grunwald, J. E., Pistilli, M., Ying, G.-S., Maguire, M. G., Daniel, E., & Martin, D. F. (2015) · Ophthalmology · doi:10.1016/j.ophtha.2014.11.007 · Cited by 204
VEGF regulates local inhibitory complement proteins in the eye and kidney
Keir, L. S., Firth, R., Aponik, L., Feitelberg, D., Sakimoto, S., Aguilar, E., Welsh, G. I., Richards, A., Usui, Y., Satchell, S. C., et al. (2016) · Journal of Clinical Investigation · doi:10.1172/jci86418 · Cited by 154
“Over 40% have stable or improved visual acuity (7), but 10%–30% of patients treated develop reduced visual acuity with regular repeated injections over time (8, 9).”
Background
Metadata
- Authors
- Young, M., Chui, L., Fallah, N., Or, C., Merkur, A. B., Kirker, A. W., Albiani, D. A., & Forooghian, F.
- Affiliations
- Praxis Spinal Cord Institute (CA)
- University of British Columbia (CA)
- Corresponding author
- Young, Mei
- Chui, Lica
- Or, Chris
- Merkur, Andrew B.
- Kirker, Andrew W.
- Albiani, David A.
- Forooghian, Farzin
- Venue
- Retina
- Published
- 2014-07
- Volume
- 34
- Issue
- 7
- Pages
- 1308-1315
- ISSN
- 0275-004X (ISSN-L)
- OpenAlex
- W1979285901
- Cited by
- 78
- References
- 4
- Citations by year
- 2025: 3 · 2024: 2 · 2023: 5 · 2022: 7 · 2021: 10 · 2020: 4 · 2019: 3 · 2018: 10 · 2017: 6 · 2016: 16 · 2015: 5 · 2014: 5
- FWCI
- 9.96
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Retina (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Retinal Imaging and Analysis
- Health Sciences › Medicine › Ophthalmology › Retinal and Macular Surgery
- Keywords
- neovascular age-related macular degeneration, retinal pigment epithelium atrophy, choroidal atrophy, anti-VEGF therapy, bevacizumab, ranibizumab, treatment side effects, choroidal thickness, disease progression
- MeSH terms
- Bevacizumab, Ranibizumab, Aged, 80 and over, Atrophy, Choroid, Female, Humans, Male, Postoperative Complications, Retrospective Studies, Disease Progression, Angiogenesis Inhibitors, Tomography, Optical Coherence, Vascular Endothelial Growth Factor A, Retinal Pigment Epithelium, Wet Macular Degeneration, Intravitreal Injections, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Exacerbation of choroidal and retinal pigment epithelial atrophy after anti-vascular endothelial growth factor treatment in neovascular age-related macular degeneration. https://app.cochat.ai/papers/10.1097/iae.0000000000000081
- The paper
- Young, M., Chui, L., Fallah, N., Or, C., Merkur, A. B., Kirker, A. W., Albiani, D. A., & Forooghian, F. (2014). Exacerbation of choroidal and retinal pigment epithelial atrophy after anti-vascular endothelial growth factor treatment in neovascular age-related macular degeneration. Retina. https://doi.org/10.1097/iae.0000000000000081
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.